<DOC>
	<DOCNO>NCT01166724</DOCNO>
	<brief_summary>The investigator hypothesize Tacrolimus ( Tac ) withdrawal Tac , MMF steroid base triple therapy regimen lead long term improved/stabilized graft function ( glomerular filtration rate , GFR ) primarily consequence halt CNI-induced fibrogenetic process mediate loss function renal tissue . The investigator hypothesize underlying fibrotic mechanism mediate pathophysiologic process promote epithelial mesenchymal transition ( EMT ) ( mediate TGF- ƒÒ ) early therapeutic intervention may reverse process ( mediate BMP-7 ) 4 . To address hypothesis investigator propose follow clinical mechanistic aim : The investigator test hypothesis switch Tac SRL Tac base triple therapy regimen MMF steroid live deceased donor renal transplant recipient lead improvement allograft structure function 2 year post-transplantation . The investigator test hypothesis open label control trial stable renal allograft recipient Tac , MMF , prednisone maintenance immunosuppression undergo renal biopsy 3-4 month post-transplantation randomize either ) Remain Tac , MMF prednisone ( CNI-maintenance ) b ) switch Tac SRL continue MMF prednisone . The investigator compare biopsy derive measure allograft fibrosis ( CADI , Sirius Red , Banff Chronicity Index ) GFR two group</brief_summary>
	<brief_title>Renal Allograft Function Histology Following Switching From A Tacrolimus Sirolimus ( SRL ) -Based Immunosuppression-</brief_title>
	<detailed_description>We test hypothesis open label control trial stable renal allograft recipient Tac , MMF , prednisone maintenance immunosuppression undergo renal biopsy 3-4 month post-transplantation randomize either ) Remain Tac , MMF prednisone ( CNI-maintenance ) b ) switch Tac SRL continue MMF prednisone . We compare biopsy derived measure allograft fibrosis ( CADI , Sirius Red , Banff Chronicity Index ) GFR two group</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Absence clinical acute rejection posttransplant period precede randomization 2 . HLAmismatched solitary first second kidney transplant recipients 3 . Absence degree rejection ( Banff 2007 ) renal biopsy 36 month ( +/ 2 month ) posttransplant . 4 . Absence posttransplant donorspecific antibody 1 . HLAidentical transplant 2 . Contraindication inability undergo renal biopsy , like previous complication due biopsy , anticoagulation , active infection , etc . 3 . Positive flow cross match , sensitize recipient , presence donorspecific antibody . 4 . Rejection episode transplantation , either cellular humoral cause renal biopsy . 5 . Rejection present prerandomization renal biopsy . 6 . Proteinuria great 0.3 gram/day 7 . Native kidney disease biopsy proven likely glomerulonephritis , primary recurrent FSGS , MPGN primary recurrent membranous GN . 8 . Hypertriglyceridemia &gt; 400 mg/dL ( treat ) , LDL cholesterol &gt; 160 mg/dL optimal treatment . 9 . WBC &lt; 2000/mm3 , ANC &lt; 1000 mm3 , Platelet count &lt; 100,000 mm3 10 . Active wound issue . 11 . Primary nonfunction . 12 . Active BKV CMV disease . 13 . Evidence recurrent disease . 14 . Active infection 15 . Pregnancy 16 . Women childbearing potential unable unwilling use birth control study . 17. e GFR ≤ 40 ml/ min screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Kidney transplant</keyword>
</DOC>